Sponsors (2)
Official title: Extend expiring health provisions and improve health care delivery.
Introduced March 6, 2025 by Ronald Lee Wyden · Last progress March 6, 2025
The bill boosts health‑care access, public‑health preparedness, and transparency (especially around drug pricing and PBMs) while imposing substantial new federal spending, broad data‑reporting rules, and compliance burdens that could raise costs, privacy risks, and implementation challenges for states, small providers, and plans.
Medicare, employer, and Medicaid plan members (patients, employers, and sponsors) gain far greater drug‑price and PBM transparency — including machine‑readable, claim‑level reports, rebate pass‑through rules, and audit rights — enabling plans and consumers to spot high‑cost drugs and hidden middleman revenue and potentially lower out‑of‑pocket costs.
Low‑income, rural, and underserved patients get expanded access to primary and specialty care through multi‑year increases in funding for community health centers, the National Health Service Corps, teaching health center GME slots, diabetes and WTC programs, dental programs, sickle cell programs, and cancer screening initiatives.
Federal public‑health preparedness and surveillance are strengthened — more funding and authorities for hospital preparedness, regional biocontainment labs, wastewater surveillance, AMR strategy, stockpile transparency, and surge personnel reassignments improve readiness for pandemics and biological threats.
Wide‑ranging new reporting, audit, and documentation requirements for PBMs, plans, pharmacies, hospitals, and states create large compliance costs and administrative burdens that will likely be passed on through higher premiums, fees, or reduced provider/rebate margins for patients and employers.
The bill authorizes substantial new federal spending across health centers, preparedness, labs, SAMHSA, and other programs — increasing taxpayer obligations and putting pressure on budgets or requiring offsets.
Extensive data collection and broader disclosures (claims‑level drug data, PBM commercial data, wastewater surveillance, expanded reporting) raise privacy and proprietary risks — potential re‑identification of health information and exposure of confidential commercial arrangements.
Based on analysis of 36 sections of legislative text.
Imposes broad PBM reporting and contract rules, streamlines out‑of‑State Medicaid enrollment for children, adjusts Medicare/DSH rules and timing, funds public health programs, and reforms pediatric drug and biosimilar patent rules.
Requires new transparency and reporting from pharmacy benefit managers (PBMs) to group health plans, Medicare Part D, and employer plans and imposes PBM contract and disclosure rules. Makes multiple Medicaid and Medicare payment and enrollment changes (including streamlined out‑of‑State provider enrollment for children on Medicaid, hospital payment adjustment rules, and date extensions for certain Medicare hospital programs), funds and reauthorizes a range of public health and workforce programs, tightens pediatric cancer drug study requirements, caps certain patents asserted in biosimilar litigation, extends temporary fentanyl analogue scheduling, and adds public‑health preparedness investments such as regional biocontainment lab grants. The bill is large and omnibus in scope: it combines PBM transparency and reporting across statutory codes (Public Health Service Act, Social Security Act, ERISA/IRC references), Medicaid and Medicare payment and operational changes, new/extended appropriations and authorizations for community health centers, workforce programs, maternal and child health initiatives, and targeted FDA and controlled‑substance amendments. Many provisions include phased or delayed effective dates and give agencies rulemaking or implementation authority, and some changes (PBM, pediatric drug, patent limits) are likely to prompt industry and stakeholder debate.